Skip to main content

Table 2 Results from the reference case probabilistic analysis (95% confidence intervals)

From: Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis

Treatment

Cost (CAD$)

Effect (QALYs)

Incremental Cost

Incremental Effect

ICER

BREN + AVD

$411,190

9.62

$192,336

0.46

$418,122

($300,490–$554,715)

(7.29–11.0)

ABVD

$218,854

9.16

($156,367–$310,743)

(6.98–10.49)